GHRP-2 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: GHRP-2 endocrine challenge evidence

Growth Signal Research peptide Lyophilized verified

Also known as: Pralmorelin, GHRP2

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

2 mg, 5 mg, 10 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Salt and supplier formulation dependent

Catalog Description

GHRP-2 (Pralmorelin) activates GHS-R1a to stimulate GH release, and also produces some off-target activation of non-GHS-R1a/CRF-related pathways, resulting in mild ACTH, cortisol, and prolactin co-stimulation - less pronounced than hexarelin but present, unlike the highly selective ipamorelin. It also has moderate appetite-stimulating activity, weaker than GHRP-6.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Short; a precise SC half-life is not established in a validated human product

Onset

Acute GH and pituitary-hormone responses occur within the first hours after IV challenge

Administration Routes (Research)

IV in human challenge studiesSC use is unapproved community practice

Reported Research Effects

GH release via GHS-R1a agonism
Mild ACTH/cortisol/prolactin co-stimulation
Moderate appetite stimulation (less than GHRP-6)

Reported Research Side Effects

Transient flushing or appetite effects
Increased prolactin ACTH and cortisol in human challenge studies
Long-term safety is unknown

Data source: Primary human endocrine studies and GHRP review

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

1-2 mcg/kg as a single endocrine challenge dose [IV; Single-dose human study; Once]Source: PMID 9285939
No validated chronic SC regimen is established [SC; Not established; Not established]Source: evidence gap

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Other GH secretagogues
Active malignancy or conditions where increased GH or IGF-1 signaling is undesirable

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

The former 100-300 mcg one-to-three-times-daily SC schedules were duplicated community protocols and were removed. Published human work largely consists of acute endocrine challenge studies.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

GHRP-2 and hexarelin pituitary responses — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/9285939/

Growth hormone-releasing peptides review — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/16822960/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.